Biotech Sector a Healthy Choice for Investors?
(Nasdaq: $ELTX) (Nasdaq: $VRDN) (Nasdaq: $KZIA) (Nasdaq: $RGLS)
Focus on Life Sciences; (Nasdaq: $AUVI) (CSE: $BETR.CN) (OTC: $FLHLF)
(NASDAQ: $OTRK)
April 5, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s
roundup of stocks to watch in the Biotech/Life Sciences sector.
Read this in full at: https://www.investorideas.com/news/2024/main/04051Stocks.asp
The newest biotech companies offer therapies for
cancer, eye disease and microRNA.
The latest life sciences companies work in the fields
of smart building tech for healthcare facilities, neuro-psychiatric treatment, psychedelic
drug development and AI and telehealth-enabled healthcare.
New Stocks Added to
the Biotech Directories:
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a
clinical-stage biotechnology company developing a pipeline of novel
immunotherapies for the treatment of cancer. By combining expertise in
immunology and immunotherapy, Elicio is engineering investigational Amphiphile
(“AMP”) immunotherapies intended to precisely target and fully engage the lymph
nodes, the site in our bodies where the immune response is orchestrated. Elicio
is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and
vaccines for an array of aggressive cancers.
Viridian Therapeutics, Inc. (Nasdaq:VRDN) is a biopharmaceutical company focused on engineering and developing
potential best-in-class medicines for patients with serious and rare diseases.
Viridian’s expertise in antibody discovery and protein engineering enables the
development of differentiated therapeutic candidates for previously validated
drug targets in commercially established disease areas. Viridian is advancing
multiple candidates in the clinic for the treatment of patients with thyroid
eye disease (TED). The company is conducting two global Phase 3 clinical trials
(THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as
a potential best-in-class intravenous therapy followed by VRDN-003 as a
potential first- and best-in-class subcutaneous therapy for the treatment of
TED.
In addition to its TED portfolio, Viridian is
advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors,
including VRDN-006 and VRDN-008, which has the potential to be developed in
multiple autoimmune diseases.
Kazia Therapeutics (Nasdaq:KZIA) is an oncology-focused drug development company, based in Sydney,
Australia. Our lead program is paxalisib, an investigational brain-penetrant
inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat
multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib
is or has been the subject of ten clinical trials in this disease. A completed
Phase 2 study in glioblastoma reported early signals of clinical activity in
2021, and a pivotal study in glioblastoma, GBM AGILE, is ongoing, with final
data expected in 1H2024. Other clinical trials are ongoing in brain metastases,
diffuse midline gliomas, and primary CNS lymphoma, with several of these having
reported encouraging interim data. Kazia is also developing EVT801, a
small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April
2021. Preclinical data has shown EVT801 to be active against a broad range of
tumour types and has provided evidence of synergy with immuno-oncology agents.
A Phase I study is ongoing and preliminary data is anticipated in CY2024.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a
biopharmaceutical company focused on the discovery and development of
innovative medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop a pipeline
complemented by a rich intellectual property estate in the microRNA field.
Regulus maintains its corporate headquarters in San Diego, CA.
Applied UV, Inc. (Nasdaq: AUVI) is dedicated to
developing and acquiring smart building technologies for healthcare,
hospitality, commercial and municipal markets. With SteriLumen, MunnWorks, LED
Supply Co., and PURO, the company has a diverse portfolio that addresses
various needs in the market. Applied UV Inc. is committed to innovation and
excellence in providing solutions for a healthier and smarter world.
A BetterLife Pharma (CSE:BETR; OTC: BETRF) is an emerging
biotechnology company primarily focused on developing and commercializing two compounds,
BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001,
which is in preclinical and IND-enabling studies, is a non-hallucinogenic and
non-controlled LSD derivative in development and it is unique in that it is unregulated
and therefore can be self-administered. BetterLife’s synthesis patent for
BETR-001 eliminates regulatory hurdles and its pending patent, for composition
and method of use, covers treatment of major depressive disorder, anxiety
disorder and neuropathic pain and other neuro-psychiatric and neurological
disorders. BETR-002, which is in preclinical and IND-enabling studies, is based
on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s
pending method of use and formulations patent covers treatment of anxiety
related disorders including benzodiazepine dependency. BetterLife also owns a
drug candidate for the treatment of viral infections such as COVID-19 and is in
the process of seeking strategic alternatives for further development.
Filament Health (NEO:FH; OTC:FLHLF) is a clinical-stage natural psychedelic drug
development company. We believe that safe, standardized, naturally-derived
psychedelic medicines can improve the lives of many, and our mission is to see
them in the hands of everyone who needs them as soon as possible. Filament's
platform of proprietary intellectual property enables the discovery,
development, and delivery of natural psychedelic medicines for clinical
development. We are paving the way with what we believe to be the first-ever
natural psychedelic drug candidates.
Ontrak, Inc. (NASDAQ: OTRK) is a leading AI
and telehealth-enabled healthcare company, whose mission is to help improve the
health and save the lives of as many people as possible. Ontrak identifies,
engages, activates, and provides care pathways to treatment for the most
vulnerable members of the behavioral health population who would otherwise fall
through the cracks of the healthcare system. We engage individuals with
anxiety, depression, substance use disorder and chronic disease through
personalized care coaching and customized care pathways that help them receive
the treatment and advocacy they need, despite the socio-economic, medical and
health system barriers that exacerbate the severity of their comorbid
illnesses. The company’s integrated intervention platform uses AI, predictive
analytics and digital interfaces combined with dozens of care coach engagements
to deliver improved member health, better healthcare system utilization, and
durable outcomes and savings to healthcare payors.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
Research
more biotech stocks with Investorideas Biotech stock directory
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all. Our original branded content includes podcasts such as Exploring
Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for various sectors, including gaming, biotech,
tech and sports. Public companies within the sectors we cover can use our news
publishing and content creation services to help tell their story to interested
investors. Paid content is always disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media,
podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact
Investorideas.com to be added to our stock directories or learn more about us
Dawn Van Zant and Cali Van Zant
800
665 0411
No comments:
Post a Comment